Strategic Acquisition Biologics, Inc. is now part of McKesson, signaling a strategic alignment that could open broader distribution, payer access, and bundled oncology therapies opportunities through a larger, integrated healthcare network.

Oncology Focus With a specialization in oncology and complex therapeutic areas, there is potential to expand CABLIVI and other high-touch, specialty medications through expanded product listings and patient access programs within McKesson's ecosystem.

New Partnerships Recent partnerships, including Taiho Oncology and Sanofi Genzyme, indicate a channel-ready environment for co-promotions, exclusive distribution, and joint patient support initiatives that can be scaled.

Patient Access Programs Biologics has invested in full-service patient support (TARPEYO Touchpoints) and access services, presenting opportunities to upsell or cross-sell expanded payer assistance, prior authorization support, and affordability programs.

Growth Signals Revenue in the mid-range of tens of millions and McKesson’s Fortune 500 backing suggest a stable platform for expanding specialty pharmacy services, digital marketing integration, and analytics driven sales outreach across oncology and rare disease channels.